Turn Therapeutics (TTRX) Non-Current Deffered Revenue (2024 - 2026)

Turn Therapeutics' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.4 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue steadied at $1.4 million in Q1 2026 per TTRX's latest filing, from $1.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $1.4 million in Q4 2024 and bottomed at $1.4 million in Q4 2024.
• The 3-year median for Non-Current Deffered Revenue is $1.4 million (2024), against an average of $1.4 million.
• Biggest YoY gain for Non-Current Deffered Revenue was 0.0% in 2025; the steepest drop was 0.0% in 2025.
• Year by year, Non-Current Deffered Revenue stood at $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025, then changed by 0.0% to $1.4 million in 2026.
• Per Business Quant, the three latest TTRX Non-Current Deffered Revenue figures stand at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025).